SYHA1807 / WuXi AppTec, CSPC Pharma - LARVOL DELTA

Development and validation of a UPLC-MS/MS method for determination of SYHA1807 in a first-in-human study. (PubMed, Bioanalysis) - "The established method was fully validated according to bioanalytical guidelines. Results & A rapid, specific and robust UPLC-MS/MS method was first established for quantifying SYHA1807 and successfully applied in a first-in-human study."

Journal • P1 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov) - P1; N=71; Not yet recruiting; Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Clinical • New P1 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Thoracic Cancer